10
Participants
Start Date
February 28, 2009
Primary Completion Date
January 31, 2012
Study Completion Date
April 30, 2013
Bendamustine HCL
bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
Arizona Cancer Center, Tucson
Collaborators (1)
Cephalon
INDUSTRY
University of Arizona
OTHER